



Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool That Exploits Genomic Data in Public Health and Clinical Microbiology Applications

 Charlene M. C. Rodrigues,^{a,b}  Keith A. Jolley,^a Andrew Smith,^{c,d} J. Claire Cameron,^e Ian M. Feavers,^a  Martin C. J. Maiden^a

^aDepartment of Zoology, University of Oxford, Oxford, United Kingdom

^bPaediatric Infectious Diseases Unit, St. George's University Hospitals NHS Foundation Trust, London, United Kingdom

^cGlasgow Dental School, University of Glasgow, Glasgow, United Kingdom

^dScottish Microbiology Reference Laboratory, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom

^ePublic Health Scotland, Glasgow, United Kingdom

ABSTRACT As microbial genomics makes increasingly important contributions to clinical and public health microbiology, the interpretation of whole-genome sequence data by nonspecialists becomes essential. In the absence of capsule-based vaccines, two protein-based vaccines have been used for the prevention of invasive serogroup B meningococcal disease (IMD) since their licensure in 2013 and 2014. These vaccines have different components and different levels of coverage of meningococcal variants. Hence, decisions regarding which vaccine to use in managing serogroup B IMD outbreaks require information about the index case isolate, including (i) the presence of particular vaccine antigen variants, (ii) the expression of vaccine antigens, and (iii) the likely susceptibility of its antigen variants to antibody-dependent bactericidal killing. To obtain this information requires a multitude of laboratory assays, impractical in real-time clinical settings, where the information is most urgently needed. To facilitate assessment for public health and clinical purposes, we synthesized genomic and experimental data from published sources to develop and implement the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index, which is publicly available on PubMLST (<https://pubmlst.org>). Using whole-genome sequences or individual gene sequences obtained from IMD isolates or clinical specimens, the MenDeVAR Index provides rapid evidence-based information on the presence and possible immunological cross-reactivity of different meningococcal vaccine antigen variants. The MenDeVAR Index enables practitioners who are not genomics specialists to assess the likely reactivity of vaccines for individual cases, outbreak management, or the assessment of public health vaccine programs. The MenDeVAR Index has been developed in consultation with, but independently of, both the 4CMenB (Bexsero; GSK) and rLP2086 (Trumenba; Pfizer, Inc.) vaccine manufacturers.

KEYWORDS meningococcal disease, *Neisseria meningitidis*, vaccines, Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR), meningococcal antigen typing system (MATS), meningococcal antigen surface expression (MEASURE) assay, serum bactericidal activity assay, outbreaks, whole-genome sequencing, public health

Microbial whole-genome sequencing (WGS) has advanced our understanding of microbial evolution, diversity, and pathogenicity. Since the first bacterial genome was sequenced in 1995, the technology has developed from dideoxynucleotide terminator (Sanger) sequencing to multiplexed WGS platforms (1–3). Concomitantly, the cost

Citation Rodrigues CMC, Jolley KA, Smith A, Cameron JC, Feavers IM, Maiden MCJ. 2021. Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. *J Clin Microbiol* 59:e02161-20. <https://doi.org/10.1128/JCM.02161-20>.

Editor Daniel J. Diekema, University of Iowa College of Medicine

Copyright © 2020 Rodrigues et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Martin C. J. Maiden, martin.maiden@zoo.ox.ac.uk.

Received 18 August 2020

Returned for modification 29 September 2020

Accepted 9 October 2020

Accepted manuscript posted online 14 October 2020

Published 17 December 2020

of WGS has decreased substantially, increasing its availability and affordability worldwide; however, DNA sequencing itself is a first step, with multidisciplinary expertise required to exploit these complex large data sets to address particular questions and translate the results to public health action. Genomic technologies are increasingly incorporated into public health and clinical microbiology laboratories, where identifying and typing microorganisms are critical to informing infectious disease management in individuals and populations. Extracting information from genomic data is important, but it is equally important to communicate these data promptly and effectively to relevant practitioners (4). Here, we describe a generalizable framework for assimilating sequence data with phenotypic information, linking genotype to phenotype with the results presented in an easy-to-understand format for use by nonspecialists.

Invasive meningococcal disease (IMD), caused by *Neisseria meningitidis*, is a serious infection with significant mortality and morbidity (5, 6). Diagnosis of IMD is either through bacterial culture and capsular group serotyping or, in the absence of culture, by PCR testing, with additional discrimination provided by characterization of capsule-encoding and protein antigen-encoding genes (7). IMD generally occurs sporadically, but it can occur in clusters and outbreaks, due to the transmission of hyperinvasive meningococcal variants generally or among individuals living in closed or semiclosed communities, such as schools, universities, military barracks, and extended households. Increasingly, real-time WGS of meningococcal isolates can direct public health investigations and interventions.

Prevention of IMD is possible by immunization, delivered either by routine programs or in response to clusters or outbreaks. When they occur, such outbreaks are a public health priority, requiring the rapid identification of individuals at high risk from the meningococcal variant identified in the index case. Prophylactic antibiotics are provided to close contacts to prevent outbreak strain transmission, and vaccination is offered where appropriate (8). While highly immunogenic conjugate protein-polysaccharide vaccines are available against invasive meningococci expressing capsular serogroups A, C, W, and Y (9), there are none against serogroup B meningococci, which are a major cause of IMD outbreaks and clusters in many countries. In 2013 and 2014, two protein-based meningococcal vaccines were licensed to assist in the prevention of serogroup B IMD. The particular protein antigens contained in the two vaccines, 4CMenB (Bexsero; GSK) and rLP2086 (Trumenba; Pfizer, Inc.), were different and not specific to serogroup B meningococci. These antigens also displayed immunologically significant protein sequence diversity (10, 11). Therefore, the two vaccines exhibit different degrees of possible protection against heterologous vaccine antigens, and consequently, there could be a need for frontline clinical and public health specialists to assess each vaccine rapidly in the context of a particular scenario, to inform decisions about vaccine implementation.

Using WGS to provide clinically applicable information requires systematic and reproducible characterization of genetic variation. Multilocus sequence typing (MLST), based on housekeeping genes, is the most widely used approach to characterizing bacterial variants, facilitating communication among laboratories internationally and the identification of hyperinvasive meningococci (12). Typing of bacterial genetic diversity of medically important features, such as polysaccharide capsules (13, 14), antimicrobial resistance genes (15), and vaccine antigens (16), can be achieved through similar gene-by-gene approaches (17). For example, the Bexsero antigen sequence typing (BAST) scheme was established to characterize and describe vaccine antigen variants, using data derived through WGS or sequencing of individual genes (16).

Both vaccines contain factor H binding protein (fHbp): one recombinant peptide variant in Bexsero (peptide 1) and two native lipidated peptide variants in Trumenba (peptides 45 and 55) (11). Bexsero also contains the recombinant proteins neisserial heparin-binding antigen (NHBA [peptide 2]) and *Neisseria* adhesin A (NadA [peptide 8]), combined with the PorA-containing (variable region 2 [VR2]; peptide 4) outer membrane vesicle from the MeNZB vaccine (10). The BAST scheme catalogues peptide presence/absence and variation, using deduced peptide sequences, but cannot infer

protein expression or cross-reactivity. The meningococcal antigen typing system (MATS) laboratory assay was devised to estimate the proportion of diverse serogroup B disease strains prevented by Bexsero, by assessing protein expression and cross-reactivity (18); however, MATS is not widely or immediately available in clinical settings and is time- and resource-intensive. Genetic MATS (gMATS) was developed to predict Bexsero strain coverage using sequence and phenotypic MATS data. At the time of writing, this algorithm was not available on an accessible, integrated platform for genome sequence data analysis, nor had it been updated to accommodate the description of additional variants (19).

To perform genomic vaccine antigen analysis comprehensively requires an understanding of sequencing technology, genomic data quality control, and gene/peptide curation and analysis. As of mid-2020, these skills were developing among health care scientists/clinicians, but were far from universal (4). Given the need to assess breadth of vaccine reactivity and to ensure genomic data are harnessed to maximize clinical and public health benefit, we developed the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index, publicly accessible on the PubMLST *Neisseria* website (20). By synthesizing published, peer-reviewed, experimental data with sequence data, the MenDeVAR Index provides a means for public health and clinical practitioners to extract easily understood, relevant information from genomic data in real time.

MATERIALS AND METHODS

Vaccine antigen typing. Allele-based typing schemes for each of the antigens included in Bexsero and Trumenba have been published. The BAST scheme was developed as a multilocus, rapid, and scalable method to catalogue deduced peptide diversity of meningococcal vaccine antigens (16). The scheme includes five peptide components contained in the Bexsero vaccine: fHbp, NHBA, NadA, and PorA VR1 and VR2. Typing of Trumenba vaccine antigen fHbp was available with cross-referencing to the subfamily A and B nomenclature on the PubMLST *Neisseria* website (21, 22). Novel peptide variants are curated in real time after submission to PubMLST; these curated databases form the basis of the MenDeVAR Index.

Literature search. Determining the extent to which either protein-based vaccine is protective against a given meningococcus requires an assessment for each vaccine component of the protein sequence variant present, its surface expression, its likely recognition by vaccine-induced antibodies, and finally the likelihood of bactericidal killing of the meningococcus in the presence of vaccinee serum. These factors were assessed using published experimental studies for each vaccine. For Bexsero, the MATS assay was used, which was established to assess the breadth of vaccine coverage to diverse meningococcal strains (18, 23). MATS determines the antigenic variants of fHbp, NHBA, and NadA through sandwich enzyme-linked immunosorbent assay (ELISA) and their reactivity to pooled toddler serum (postvaccination with three doses and booster), based on a collection of reference strains tested in serum bactericidal activity (SBA) assays. For Trumenba, the meningococcal antigen surface expression (MEASURE) assay (24), a flow cytometric measurement of fHbp surface expression, was used. Additionally, SBA assays using serum from individuals immunized with Trumenba (2 or 3 doses on various dosing schedules) were included, as there was only one vaccine antigen. Only antigens tested in these assays were analyzed as contributing to a cross-protective vaccine effect for the MenDeVAR Index (Fig. 1).

For Bexsero, a literature search using the terms "meningococcal antigen typing system," "*Neisseria meningitidis*," and "vaccine" on 14 May 2020 yielded 44 studies published in English. There were 13 studies eligible for assessment (see Table S1 in the supplemental material), pertaining to capsular group B IMD isolates (MATS is only validated for serogroup B), with data of sufficient detail to assess individual antigens and their predicted vaccine coverage. For Trumenba, a literature search using the terms "meningococcal antigen surface expression (MEASURE) assay," "*Neisseria meningitidis*," and "vaccine" on 14 May 2020 yielded 12 studies published in English. One study contained MEASURE assay data for individual antigenic variants (see Table S2 in the supplemental material). Additionally, a literature search using the terms "serum bactericidal activity assay," "*Neisseria meningitidis*," "vaccine," and "bivalent" on 14 May 2020 yielded 28 studies published in English. Fifteen studies contained data to assess individual antigenic variants and their likelihood of providing protection using SBA assays (Table S2).

Criteria for defining cross-reactive antigens in the MenDeVAR Index. To index the experimental data, thresholds were determined to define antigenic variants as either likely cross-reactive or not cross-reactive, and the proportion of isolates with a given antigenic variant considered covered/protected through experimental assays was calculated. For each assay (MATS, MEASURE, and SBA), thresholds previously defined by the developers or the research community were employed. For the MATS assay, an antigenic variant was considered "covered" (i.e., would be susceptible to a vaccine-induced immune response) where the relative potency (RP) was greater than the positive bactericidal threshold (PBT) (18). For the MEASURE assay, an antigenic variant was considered "covered" if the mean fluorescent intensity (MFI) was $>1,000$ (24). For the SBA assay, antigenic variants were assessed through host immunogenicity, resulting in likely protection from infection. The accepted serological measure indicating likely protection by immunization with meningococcal vaccines is either a ≥ 4 -fold rise in




FIG 1 The Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index algorithm used to identify which antigens are included as cross-reactive in the combined analysis of published experimental data from the meningococcal antigen typing system (MATS) (18), the meningococcal antigen surface expression (MEASURE) assay (24), and the serum bactericidal activity (SBA) assay (27). RP, relative potency; PBT, positive bactericidal threshold; MFI, mean fluorescence intensity.

antibody titers between pre- and postvaccination sera or a titer of >1:4 (25, 26). From the combined analysis of the experimental studies, if an antigenic variant had been tested in ≥ 5 isolates and $\geq 3/4$ of them were covered/protected, then the variant was considered cross-reactive (amber). If an antigenic variant had been tested in ≥ 5 isolates, and $\geq 3/4$ of them were not covered/protected, then the variant was considered not cross-reactive (red) (Fig. 1).

Development of data visualization for the MenDeVAR Index. For ease of data presentation, a red, amber, green “traffic light” data interpretation was employed: “green” was assigned to meningococcal variants with ≥ 1 antigenic vaccine variant, based on exact peptide sequence match, “amber” was assigned to isolates with ≥ 1 antigenic variant demonstrated as cross-reactive in experimental studies, and “red” was assigned to isolates where all antigenic variants were not exact matches and had been shown to not elicit cross-reactivity to vaccine variants. The designation “gray” was assigned to variants possessing antigenic variants untested in experimental assays at the time of writing or where such tests did not meet the threshold chosen to indicate cross-reactivity. The MenDeVAR Index status of the variants, especially those designated “gray” will be updated in light of the above criteria as further published information becomes available.

The MenDeVAR Index was implemented on the PubMLST *Neisseria* website on the isolate record (Fig. 2a). In addition, WGS data or individual gene sequences can be used to make a direct query on https://pubmlst.org/bigsub?db=pubmlst_neisseria_mendevar, which outputs the MenDeVAR Index result, without the need to create isolate records or upload WGS data to the database (Fig. 2b). A written description is provided to aid those with color vision deficits, where “green” means “exact,” “amber” means “cross-reactive,” “red” means “none,” and gray means “insufficient data.” Additional supporting information is provided: (i) the antigenic determinant of the reactivity index, (ii) the assay used to determine cross-reactivity, (iii) specific references to studies including those antigens, and (iv) caveats to interpretation (Table 1). The MenDeVAR Index was also integrated with the BAST scheme (16), so the index appears as part of the BAST profile on the isolate record. Users can also perform a batch profile query selecting the BAST scheme that outputs the MenDeVAR Index (https://pubmlst.org/bigsub?db=pubmlst_neisseria_seqdef&l=1&page=batchProfiles).

Case studies. To exemplify the application of the MenDeVAR Index, two published IMD outbreaks/clusters were analyzed: an IMD outbreak among a semiclosed, Irish Traveller community from 2010 to 2013 (27) and a university IMD cluster in the United States in 2016 (28). Both WGS data available through PubMLST and published antigenic variants determined through WGS were examined.

RESULTS

Cross-reactive vaccine antigens. For Bexsero vaccine, MATS studies (29–41) were identified through literature searches. With the exception of two studies (34, 40) that used a PBT for fHbp of 0.012, all other antigen RPs were assessed against PBTs of 0.021 for fHbp, 0.294 for NHBA, and 0.009 for NadA (18). For each antigenic variant of fHbp, NHBA, and NadA, the proportion of isolates with RP > PBT was calculated. For fHbp, there were 139 peptides examined by MATS assay, 28 (20.1%) tested in ≥ 5 isolates. For NHBA, there were 110 peptides, 30 (27.3%) tested in ≥ 5 isolates. For NadA, there were 22 peptides, 5 (22.7%) tested in ≥ 5 isolates; peptide 8 is an exact sequence match but has been experimentally tested in only 3 isolates to date. For Trumenba vaccine, each antigen tested by the MEASURE assay in one study (24) was evaluated. For fHbp, there

(a)

Provenance/primary metadata

id: 19992	disease: invasive (unspecified/other)	update history: 175 updates show details
isolate: M10 240568	species: <i>Neisseria meningitidis</i>	date entered: 2012-09-05
strain designation: B: P1.22,14: F5-5: ST-213 (cc213)	serogroup: B	datestamp: 2020-10-06
country: UK [England]	genogroup: B	
continent: Europe	capsule group: B	
region: Eastern	ENA run accession: ERR170963 www.ebi.ac.uk	
year: 2010	sender: Dorothea Hill, University of Oxford, UK	
epidemiological year: 07/2010-06/2011	curator: Auto Tagger	

Secondary metadata

Vaccines

<p>Bexsero reactivity: cross-reactive </p> <p>notes</p> <p>Bexsero notes: fHbp_peptide: 15 is cross-reactive to vaccine variant - data derived from MATS assays (PMID:23414709, PMID:23588089, PMID:26686998, PMID:26950303, PMID:27355628, PMID:28366725, PMID:30135218, PMID:30592763, PMID:31770063)</p> <p>Trumenba reactivity: cross-reactive </p> <p>notes</p>	<p>Trumenba notes: fHbp_peptide: 15 is cross-reactive to vaccine variant - data derived from MEASURE assays (PMID:29535195), and SBA assays (PMID:22569484, PMID:22718089, PMID:23352429, PMID:26407272, PMID:26707218, PMID:26803328, PMID:26835974, PMID:27745812, PMID:27846061, PMID:28196734, PMID:28566335, PMID:29236639)</p>
---	---

(b)

MenDeVAR (Meningococcal Deduced Vaccine Antigen Reactivity) Index

Please paste in your sequence to query against the database. Please note that this may take a while (~60 s) for a genome assembly.

Enter query sequence (single or multiple contigs up to whole genome in size) Alternatively upload FASTA file Action

```
GTGAACCGAA CTACTTCTG CTGCCTTCT CTGACCGCG CCCTGATCT GACCGCTGC
AECACGAGB GCBCGGAAB CGAGCGGCG GGTGTCGCG CCGACATCG CCGGSCCTT
GCCBATGAC TAACCGGAC GCCTGACGAT AAGACAAAG GTTGAATC CCTGACATG
AAGACTCCA TTTCCTAAA CGGACACTG ACCCTGTG CACAAGTSC GGAAGAACT
TTCAGAGCG GCGACAGAB CAGAGCTCT AGCAGGCA NACTGABAA CGACAAATC
AECGCTTGC ACTTTATCG TCAATCGAA GTGGACGGC AGCTCATTAC CTTGAGAGC
```

Select FASTA file:

 |

Matches

fHbp_peptide: 15
 NHBA_peptide: missing
 NadA_peptide: missing
 PorA_VR2: missing

Vaccine cross-reactivity

Bexsero®

Explanation:

• fHbp_peptide: 15 is cross-reactive to vaccine variant - data derived from MATS assays (PMID:23414709, PMID:23588089, PMID:26686998, PMID:26950303, PMID:27355628, PMID:28366725, PMID:30135218, PMID:30592763, PMID:31770063)

Notes:

cross-reactive Bexsero® (4CMenB) is a multicomponent vaccine.

© 2010-2019 Meningococcal Vaccine Variant Antigen Reactivity Database. Please contact meningococcal@pubmlst.org for more information.

▼

Trumenba®

Explanation:

• fHbp_peptide: 15 is cross-reactive to vaccine variant - data derived from MEASURE assays (PMID:29535195), and SBA assays (PMID:22569484, PMID:22718089, PMID:23352429, PMID:26407272, PMID:26707218, PMID:26803328, PMID:26835974, PMID:27745812, PMID:27846061, PMID:28196734, PMID:28566335, PMID:29236639)

Notes:

cross-reactive Trumenba® (LP2086) is a bivalent fHbp-containing vaccine.

FIG 2 (a) The Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index as it appears on the isolate record page of the <https://pubmlst.org/neisseria/> website. The provenance data show the PubMLST ID no. is 19992 and state that this is a serogroup B meningococcal isolate from the eastern region of the United Kingdom, collected from invasive disease in 2010. The MenDeVAR Index is shown under the secondary metadata heading and shows this isolate contains cross-reactive antigens for both vaccines, with fHbp peptide 15 the antigen used to determine this through the MATS assay for Bexsero and the MEASURE and SBA assays for Trumenba; the reference is shown with the PubMed ID no. (PMID). (b) The Web interface to search using the genome sequence, individual genes, or whole-genome data to output the MenDeVAR Index.

were 9 peptides examined by MEASURE assay, 6 of which were tested in ≥ 5 isolates (Table 2). From SBA studies (42–56), there were 23 fHbp peptides examined by SBA assay, 23 (100.0%) tested in ≥ 5 isolates; peptide 55 is an exact sequence match but has not been experimentally tested to date.

Antigenic variants that did not meet either the cross-reactive or not cross-reactive threshold were designated “gray,” indicating that insufficient data were available to

TABLE 1 The caveats that are listed on the PubMLST *Neisseria* website when interpreting the MenDeVAR Index^a

Parameter	Caveat(s) for both vaccines (unless otherwise stated)
Source of data	These data combine multiple sources of information, including peptide sequence identity through whole-genome sequencing, experimental assays developed as indirect measures of the breadth of vaccine protection against diverse meningococci, and assays developed to assess immunogenicity.
Protein expression	We have not inferred protein expression from genomic data; therefore, there may be isolates that possess genes but do not express the protein <i>in vivo</i> .
Cross-reactivity definition	An antigenic variant was considered cross-reactive if it had been tested in ≥ 5 isolates/subjects and was above the accepted threshold in $\geq 3/4$ of those isolates. This was established through combined analysis of published experimental studies (PubMLST ID no. [PMID] provided for each variant), not from genomic data.
Meningococcal isolate source	These assays were based on serogroup B disease isolates for both vaccines.
Experimental assays	
Bexsero	MATS assay
Trumenba	MEASURE assay, SBA assay
Age of vaccinees	
Bexsero vaccine	For MATS assay development, Bexsero vaccine recipients were infants who had received 3 doses of vaccine and then a booster at 12 mo. The pooled sera used for the MATS assay were taken from the toddlers at 13 mo of age.
Trumenba vaccine	The age of vaccine recipients in the experimental studies varies widely, ranging from toddlers to adults, and needs to be taken into consideration when interpreting results. Vaccine studies used different schedules and doses of vaccines.

^aMenDeVAR, Meningococcal Deduced Vaccine Antigen Reactivity; MATS, meningococcal antigen typing system; MEASURE, meningococcal antigen surface expression; SBA, serum bactericidal activity.

make an assessment for this variant. This included (i) variants tested in ≥ 5 isolates, with between 1/4 and 3/4 covered/protected (Table 2), (ii) variants tested in < 5 isolates (for Bexsero vaccine, 111 fHbp peptides, 80 NHBA peptides, and 17 NadA peptides, and for Trumenba vaccine, 3 fHbp peptides tested by MEASURE assay), or (iii) variants not tested in experimental assays.

Designation of isolates with the MenDeVAR Index. A meningococcal variant was designated “green” if it contained a ≥ 1 exact sequence match to the vaccine antigenic variants. For Bexsero, this corresponded to fHbp peptide 1, NHBA peptide 2, NadA peptide 8, and PorA VR2 4 (16, 57). Similarly, for Trumenba, this corresponded to fHbp peptide 45 or 55 (11) (Table 2). The “amber” designation was used if a meningococcus contained ≥ 1 antigenic variant deemed cross-reactive from experimental studies from any of the fHbp, NHBA, or NadA peptides (Table 2). PorA peptides are not considered cross-reactive (58). Finally, the “red” designation was used for meningococci where none of the antigens present were exact matches with the vaccine antigens and the antigen variants had been shown experimentally not to cross-react with antibodies elicited by the vaccine (Table 2).

MenDeVAR Index: exemplar case studies. (i) Irish Traveller community outbreak. Retrospective analysis of a published IMD outbreak in the Republic of Ireland from 2010 to 2013 (27) exemplified the potential use of the MenDeVAR Index in the context of a community outbreak, where a variety of clinical specimens were available. A total of eight cases were identified over 42 months (Table 3). The initial meningococcus, from case A, was not cultured, but identification and typing data were acquired by PCR amplification and sequencing of MLST loci and fine-typing of antigen-encoding genes *porA* and *fetA*. PorA VR2 antigen 4 was present, an exact peptide sequence match to Bexsero. There were insufficient data to inform the use of Trumenba, which contains only fHbp proteins. At the time of identification, case A was considered to be a sporadic case and the appropriate public health action was antibiotic prophylaxis for close contacts. Using the MenDeVAR Index, the disease-associated meningococcus would have been designated “green” for Bexsero and “gray” for Trumenba. Of the seven cases subsequently linked to this case, only two were successfully cultured and underwent WGS (cases B and H), but five could have a MenDeVAR Index inferred from fine-typing of antigen PorA, with respect to Bexsero (Table 3). Additional molecular fHbp typing of isolates would inform the use of Trumenba, in a setting where the PorA is not variant

TABLE 2 Vaccine antigen variants for the protein-based meningococcal vaccines Bexsero (4CMenB) and Trumenba (rLP2086) and their designation by the MenDeVAR Index^a

MenDeVAR Index	Antigen requirement (of fHbp, NHBA, NadA, and/or PorA VR2)	fHbp peptide(s)	NHBA peptide(s)	NadA peptide(s)	PorA VR2 peptide
Bexsero vaccine					
Green (exact)	≥1	1	2	8	4
Amber (cross-reactive)	≥1	4, 10, 12, 14, 15, 37, 110, 144, 215, 232	1, 5, 10, 113, 243, 607	3, 6	None
Red (none)	All 4	16, 19, 21, 22, 24, 25, 29, 30, 31, 45, 47, 59, 76, 109, 119	6, 9, 17, 18, 25, 30, 31, 43, 47, 63, 112, 120, 160, 187, 197	1, 21, 100	≠4
Grey (insufficient data)	None of the above	13, 321, and other antigens that have not been experimentally tested	3, 20, 21, 24, 29, 115, 118, 130, and other antigens that have not been experimentally tested	Any antigens that have not been experimentally tested	None
Trumenba vaccine					
Green (exact)	fHbp	45, 55			
Amber (cross-reactive)	fHbp	1, 4, 13, 14, 15, 16, 19, 21, 23, 25, 30, 47, 49, 76, 87, 180, 187, 252, 276, 510			
Red (none)	fHbp	None			
Grey (insufficient data)	None of the above	13, 24, or other antigens that have not been experimentally tested			

^aVaccine antigen variants for the protein-based meningococcal vaccines Bexsero (4CMenB) and Trumenba (rLP2086) are designated by color by the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index as follows: green, exact matches to the sequence variants; amber, cross-reactive in experimental studies; red, not cross-reactive in experimental studies; gray, insufficient data. fHbp, factor H binding protein; NHBA, neisserial heparin-binding antigen; NadA, *Neisseria* adhesin A; PorA VR2, porin A variable region.

4. These data identified 75% (6/8) of isolates, two with WGS, with sufficient information to designate as MenDeVAR Index “green” for Bexsero and two WGS isolates with “amber” for Trumenba (Table 3).

(ii) U.S. university cluster. A cluster of IMD occurring in the United States in 2016 (28) was examined to demonstrate the use of the MenDeVAR Index in an institutional outbreak. In this cluster, two undergraduate students at a New Jersey university were diagnosed with serogroup B IMD, with meningococci isolated from the cerebrospinal fluid of both (28). These isolates were examined in real time by WGS through the local public health department, and both were sequence type 11 (clonal complex 11) and indistinguishable (Table 3). Antigenic variant data provided in the publication were assessed, which provided data equivalent to those obtained by determining the antigenic variants through PCR and sequencing, if WGS had not been available. The meningococci causing the cluster harbored fHbp variant 2 peptide 19, an antigen that is cross-reactive with Trumenba (amber) but not cross-reactive with Bexsero (red). The meningococcal cluster strains also had (i) no *nadA* gene present (“red”), (ii) PorA 10-1 (“red”), and (iii) NHBA peptide 20, for which there is insufficient data to determine cross-reactivity with confidence (“gray”). The MenDeVAR Index therefore designated these isolates “amber” for Trumenba and “gray” for Bexsero, the latter based solely on the NHBA variant present, with the remaining antigens “red.” This information could have directed public health specialists to using Trumenba early after IMD cluster definition was met, preventing delays in health protection interventions, including mass vaccination campaigns, frequently required in university settings.

DISCUSSION

As bacterial genome sequencing has become increasingly accessible, the prospect of using genomic data for the benefit of public and individual health has become a

TABLE 3 Two examples of outbreak/clusters from published literature, showing the molecular typing data used to determine the MenDeVAR Index^a

Case	Year	Capsular group	ST	cc	PorA typing	FetA typing	fHbp peptide	NHBA peptide	NadA peptide	PorA VR1	PorA VR2	BAST	Bexsero MenDeVAR Index	Trumenba MenDeVAR Index	PubMLST id
Irish traveller community outbreak															
Case A	2010	B	Incomplete MLST profile	ST-41/44 complex	7-2, 4	F1-21	—	—	—	7-2	4	Unable to assign	Green	Grey	
Case B	2010	B	6697	ST-41/44 complex	7-2, 4	F1-21	4	607	0	7-2	4	381	Green	Amber	26834
Case C	2011	B	6697	ST-41/44 complex	7-2, 4	F5-12	—	—	—	7-2	4	Unable to assign	Green	Grey	
Case D	2012	B	Incomplete MLST profile	Unable to assign	—	—	—	—	—	—	—	Unable to assign			
Case E	2013	B	6697	ST-41/44 complex	7-2, 4	F5-12	—	—	—	7-2	4	Unable to assign	Green	Grey	
Case F	2013	B	Incomplete MLST profile	ST-41/44 complex	7-2, 4	—	—	—	—	7-2	4	Unable to assign	Green	Grey	
Case G	2013	B	No data	Unable to assign	—	—	—	—	—	—	—	Unable to assign			
Case H	2013	B	6697	ST-41/44 complex	7-2, 4	F5-12	4	truncated	0	7-2	4	Incomplete BAST profile	Green	Amber	30743
U.S. university cluster															
Case 1	2016	B	11	11	5-1, 10-1	—	19	20	0	5-1	10-1	3545	Grey	Amber	
Case 2	2016	B	11	11	5-1, 10-1	—	19	20	0	5-1	10-1	3545	Grey	Amber	

^aMenDeVAR, Meningococcal Deduced Vaccine Antigen Reactivity; ST, sequence type; cc, clonal complex; PorA VR, porin A variable region; FetA, enterobactin receptor FetA; fHbp, factor H binding protein; NHBA, neisserial heparin-binding antigen; NadA, *Neisseria* adhesin A; BAST, Bexsero antigen sequence type; —, no data.

reality. This opportunity is, however, fraught with challenges, including (i) the large and complex genomic data sets involved, (ii) the expertise required to understand the uses and limitations of WGS technologies, (iii) the increasing number and complexity of analysis tools, (iv) the requirement for skills with command line interfaces, (v) insufficient bioinformatics or genomic epidemiology training among health care practitioners and scientists, and (vi) the diversity of the information sources that need to be integrated.

Genome sequence data provide information on the presence or absence of genes associated with clinically relevant phenotypes: e.g., antibiotic susceptibility, pathogenicity, or vaccine antigens. The first step in exploiting this information is to extract relevant data for the identification of the genes and the protein variants they encode (typing). The second step is to index these types to the relevant phenotypic data. The third step is to present the result in an accessible format for non-genomics specialists to inform clinical decision-making. Here, we demonstrated the MenDeVAR Index, which combines these steps into a system for rapid, real-time assessment of protein-based meningococcal vaccine antigens for public health and clinical microbiology application.

The epidemiology of IMD varies geographically. Sporadic cases occur in countries where IMD is endemic, with clusters and outbreaks associated with high-density living conditions, such as universities, military, or travelling communities (59). Endemic and hyperendemic serogroup B IMD is problematic in many industrialized regions (60), and in the absence of group B polysaccharide vaccines, protein-based vaccines (10, 11) have been developed. When IMD clusters or outbreaks emerge, it is essential to identify contacts and implement public health interventions rapidly. These include antibiotics and vaccinations, the latter, especially, requiring timely serogroup determination of the

outbreak strain to ensure deployment of the appropriate vaccine (8). For serogroup B outbreaks, characterization of peptide antigens is required to assess whether vaccination with Bexsero and/or Trumenba is likely to prevent disease (8). At the time of writing, this assessment was only possible using the laboratory assays established during the clinical development of these vaccines to assess their breadth of antigenic coverage, namely, the MATS, MEASURE, and SBA assays (18, 24, 26). These assays, however, required growth of the causative isolate, were confined to reference laboratories in a limited number of countries, and were time-consuming and expensive to perform (28, 61). Consequently, they could not be relied upon to inform timely public health interventions. At the same time, WGS has become increasingly accessible to microbiology laboratories, often in real time or near real time. Furthermore, where meningococcal cultures were not available, PCR of fine-typing and fHbp antigens provided information that complements the phenotypic data compiled within the MenDeVAR Index. Interpreted by local microbiologists and epidemiologists in the context of other pertinent information, the MenDeVAR Index offers a pragmatic assessment of likely susceptibility of outbreak strains to vaccine-induced immunity, based on published data.

For the development of the MenDeVAR Index, robust, pragmatic criteria were used to assess the weight of evidence of potential antigenic cross-reactivity from four different sources. The SBA titer remained the accepted immune correlate of protection for assessing meningococcal vaccine efficacy; however, the SBA assay cannot be performed for routine IMD case isolates investigated as part of a public health response for many reasons, including the availability of expertise, resources, time, human complement, and infant sera. The use of MATS and MEASURE assays, as means of assessing the breadth of antigenic coverage, generated the best data available. Data from MEASURE assays, however, were limited at the time of assessment, and the MATS assay was suggested to provide a conservative estimate compared to the SBA titer (36, 38, 41). SBA data were not included for Bexsero, which as a multicomponent vaccine could induce multiple antibody responses. Although the gMATS assay also used genotypic predictors of MATS phenotype and predicted cross-reactivity in agreement with the MenDeVAR Index using similar criteria (fHbp peptides 1, 4, 10, 12, 14, 15, 37, 110, 144, 215, 224, and 232; NHBA peptides 1, 5, 10, 113, 243, 607) (19), the gMATS assay was only applicable to one of the two available protein-based vaccines. Moreover, it excluded NadA antigens as predictors, included some unpublished data, and had not been updated. The MenDeVAR Index can assist public health and microbiology specialists by compiling and indexing the complex data available in the published evaluation of hundreds of meningococcal antigenic variants—a total of 29 studies at the time of writing. The MenDeVAR Index is accessible through a user-friendly webpage (https://pubmlst.org/bigbdb?db=pubmlst_neisseria_mendevar) that facilitates the submission of WGS data as single or multiple contigs or as part of an isolate record on the PubMLST *Neisseria* website.

The case studies explored here demonstrated how the MenDeVAR Index can be used as outbreaks developed, with the Irish outbreak showing how multiple types of information can be used effectively. Had the MenDeVAR Index been available at the time, it would have supported the use of the Bexsero vaccine in this outbreak setting. The U.S. university cluster demonstrated the difficulties faced by public health specialists in combining complex data sets from multiple sources in real time to inform intervention strategies. This cluster was investigated by U.S. Centers for Disease Control and Prevention, and the isolates were sent for laboratory testing at U.S. universities, which is not a routine procedure. These analyses identified relatively low fHbp protein expression and low binding of NHBA peptide 2 antisera to the outbreak strain, suggesting reduced likelihood of bactericidal killing (28). Based on these data, along with additional information about persistence of antibody responses postvaccination, immunization of ~35,000 university students with Trumenba was recommended. The public health team acknowledged that WGS data indicated the presence or absence of particular antigenic variants, which could be compared to the respective vaccine

antigens. When variants were not exact sequence matches, however, there was no additional information available to indicate potential cross-protection offered by the vaccine. In the case of this cluster, the MenDeVAR Index would have supported the use of Trumenba solely on the basis of WGS data.

There are limitations to using the MenDeVAR Index, as it is based on WGS data linked to information from published *in vitro* MATS, MEASURE, and SBA serological studies (Table 1). These assays are not perfect surrogates of protection for a variety of reasons, including the age groups used to establish the assays and the provenance of the isolates used in their development. Furthermore, at the time of writing, the expression of the antigens could not be reliably inferred or predicted from WGS data, although some fHbp promoter and intergenic regions had been correlated with protein expression (62, 63). Finally, the MenDeVAR Index applies only to possible direct protection against IMD, with no information available about possible herd immunity due to the lack of evidence to suggest either vaccine impacted oropharyngeal carriage of serogroup B meningococci (64–66).

In conclusion, we present a generalizable multilocus gene-by-gene framework for interpreting complex genomic data sets that can be used by practitioners to address clinical questions in a timely manner. Specifically, the MenDeVAR Index combines genomic and experimental data to provide a rational, evidence-based estimate of the likelihood that either of the meningococcal protein-based vaccines offers protection against a given meningococcus. To ensure broad accessibility, the MenDeVAR Index is implemented with a “red,” “amber,” and “green” interpretive interface that is easy to use and informative for practitioners without expertise in genomic analysis. In the light of new published evidence, the MenDeVAR Index can be regularly reevaluated using the criteria described here, adjusting antigenic variant designations accordingly, to ensure that public health and clinical microbiologists globally benefit from the latest research findings.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.05 MB.

ACKNOWLEDGMENTS

This publication made use of the Neisseria Multi Locus Sequence Typing website (<https://pubmlst.org/neisseria/>) sited at the University of Oxford (20). The development of this site has been funded by the Wellcome Trust (grant no. 218205/Z/19/Z) and the European Union. Charlene Rodrigues was supported by a grant from the Thrasher Research Fund.

REFERENCES

1. Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 74:5463–5467. <https://doi.org/10.1073/pnas.74.12.5463>.
2. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM. 1995. Whole-genome random sequencing and assembly of *Haemophilus influenzae* RD. *Science* 269:496–512. <https://doi.org/10.1126/science.7542800>.
3. Forde BM, O'Toole PW. 2013. Next-generation sequencing technologies and their impact on microbial genomics. *Brief Funct Genomics* 12: 440–453. <https://doi.org/10.1093/bfpg/els062>.
4. Black A, Maccannell DR, Sibley TR, Bedford T. 2020. Ten recommendations for supporting open pathogen genomic analysis in public health. *Nat Med* 26:832–841. <https://doi.org/10.1038/s41591-020-0935-z>.
5. Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, Mallard RH, Guiver M, Newbold LS, Borrow R. 2012. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. *Vaccine* 30:3710–3716. <https://doi.org/10.1016/j.vaccine.2012.03.011>.
6. Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D. 2012. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. *Lancet Neurol* 11:774–783. [https://doi.org/10.1016/S1474-4422\(12\)70180-1](https://doi.org/10.1016/S1474-4422(12)70180-1).
7. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB. 2006. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. *J Med Microbiol* 55:887–896. <https://doi.org/10.1099/jmm.0.46288-0>.
8. Public Health England. 2013. Chapter 22. Meningococcal, p 24. *In* Ramsay M (ed), Immunisation against infectious disease. Public Health England, London, United Kingdom.
9. Finne J, Leinonen M, Makela PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. *Lancet* 2:355–357. [https://doi.org/10.1016/s0140-6736\(83\)90340-9](https://doi.org/10.1016/s0140-6736(83)90340-9).
10. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. 2012. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. *Vaccine* 30:B87–B97. <https://doi.org/10.1016/j.vaccine.2012.01.033>.
11. Jiang H-Q, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA,

- Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao X-J, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. *Vaccine* 28:6086–6093. <https://doi.org/10.1016/j.vaccine.2010.06.083>.
12. Maiden MCJ, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, Caugant DA, Feavers IM, Achtman M, Spratt BG. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. *Proc Natl Acad Sci U S A* 95:3140–3145. <https://doi.org/10.1073/pnas.95.6.3140>.
 13. Marjuki H, Topaz N, Rodriguez-Rivera LD, Ramos E, Potts CC, Chen A, Retchless AC, Doho GH, Wang X. 2018. Whole-genome sequencing for characterization of capsule locus and prediction of serogroup of invasive meningococcal isolates. *J Clin Microbiol* 57:e01609-18. <https://doi.org/10.1128/JCM.01609-18>.
 14. Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, Parkhill J, Bentley SD, Hanage WP, Lipsitch M. 2013. Population genomics of post-vaccine changes in pneumococcal epidemiology. *Nat Genet* 45:656–663. <https://doi.org/10.1038/ng.2625>.
 15. Harrison OB, Clemence M, Dillard JP, Tang CM, Trees D, Grad YH, Maiden MC. 2016. Genomic analyses of *Neisseria gonorrhoeae* reveal an association of the gonococcal genetic island with antimicrobial resistance. *J Infect* 73:578–587. <https://doi.org/10.1016/j.jinf.2016.08.010>.
 16. Brehony C, Rodrigues CM, Borrow R, Smith A, Cunney R, Moxon ER, Maiden MC. 2016. Distribution of Bexsero antigen sequence types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. *Vaccine* 34:4690–4697. <https://doi.org/10.1016/j.vaccine.2016.08.015>.
 17. Maiden MC, Jansen van Rensburg MJ, Bray JE, Earle SG, Ford SA, Jolley KA, McCarthy ND. 2013. MLST revisited: the gene-by-gene approach to bacterial genomics. *Nat Rev Microbiol* 11:728–736. <https://doi.org/10.1038/nrmicro3093>.
 18. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. *Proc Natl Acad Sci U S A* 107:19490–19495. <https://doi.org/10.1073/pnas.1013758107>.
 19. Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, Comanducci M, Lemos AP, Gorla MC, Křížová P, Mikula C, Mulhall R, Nissen M, Nohynek H, Simões MJ, Skocznyńska A, Stefanelli P, Taha M-K, Toropainen M, Tzanakaki G, Vadivelu-Pechai K, Watson P, Vazquez JA, Rajam G, Rappuoli R, Borrow R, Medini D. 2019. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. *Vaccine* 37:991–1000. <https://doi.org/10.1016/j.vaccine.2018.12.061>.
 20. Jolley KA, Bray JE, Maiden MCJ. 2018. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. *Wellcome Open Res* 3:124. <https://doi.org/10.12688/wellcomeopenres.14826.1>.
 21. Brehony C, Wilson DJ, Maiden MC. 2009. Variation of the factor H-binding protein of *Neisseria meningitidis*. *Microbiology* 155:4155–4169. <https://doi.org/10.1099/mic.0.027995-0>.
 22. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knaf M, Ooi P, Smith RP, Weise P, Wetherell M, Xie X, Zagursky R, Zhang Y, Zlotnick GW. 2004. Vaccine potential of the *Neisseria meningitidis* 2086 lipoprotein. *Infect Immun* 72:2088–2100. <https://doi.org/10.1128/IAI.72.4.2088-2100.2004>.
 23. Anderson RM, Donnelly CA, Gupta S. 1997. Vaccine design, evaluation, and community based use for antigenically variable infectious agents. *Lancet* 350:1466–1470. [https://doi.org/10.1016/S0140-6736\(97\)03255-8](https://doi.org/10.1016/S0140-6736(97)03255-8).
 24. McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, Jones TR, Li S, Zlotnick G, Vogel U, Claus H, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Wang X, Vuong J, Mayer LW, Pride MW, Jansen KU, Anderson AS. 2018. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. *mBio* 9:e00036-18. <https://doi.org/10.1128/mBio.00036-18>.
 25. Borrow R, Balmer P, Miller E. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. *Vaccine* 23:2222–2227. <https://doi.org/10.1016/j.vaccine.2005.01.051>.
 26. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D. 2006. *Neisseria meningitidis* group B correlates of protection and assay standardization—international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. *Vaccine* 24:5093–5107. <https://doi.org/10.1016/j.vaccine.2006.03.091>.
 27. Mulhall RM, Brehony C, O'Connor L, Meyler K, Jolley KA, Bray J, Bennett D, Maiden MC, Cunney R. 2016. Resolution of a protracted serogroup B meningococcal outbreak with whole genome sequencing shows inter-species genetic transfer. *J Clin Microbiol* 54:2891–2899. <https://doi.org/10.1128/JCM.00881-16>.
 28. Soeters HM, Diniz-Sklar J, Kulkarni PA, MacNeil JR, McNamara LA, Zaremski E, Chang HY, Lujan E, Granoff D, Lasky M, Montana B. 2017. Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016. *Emerg Infect Dis* 23:867–869. <https://doi.org/10.3201/eid2305.161870>.
 29. Abad R, Medina V, Stella M, Boccadifuoco G, Comanducci M, Bambini S, Muzzi A, Vazquez JA. 2016. Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with other European countries. *PLoS One* 11:e0150721. <https://doi.org/10.1371/journal.pone.0150721>.
 30. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R. 2013. The disease burden of invasive meningococcal serogroup B disease in Canada. *Pediatr Infect Dis J* 32:e20–e25. <https://doi.org/10.1097/INF.0b013e3182706b89>.
 31. Budroni S, Kleinschmidt A, Boucher P, Medini D. 2016. Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB. *Vaccine* 34:2579–2584. <https://doi.org/10.1016/j.vaccine.2016.04.009>.
 32. Mowlaboccus S, Perkins TT, Smith H, Sloots T, Tozer S, Premph LJ, Tay CY, Peters F, Speers D, Keil AD, Kahler CM. 2016. Temporal changes in BEXSERO antigen sequence type associated with genetic lineages of *Neisseria meningitidis* over a 15-year period in Western Australia. *PLoS One* 11:e0158315. <https://doi.org/10.1371/journal.pone.0158315>.
 33. Mulhall RM, Bennett D, Cunney R, Borrow R, Lucidarme J, Findlow J, Jolley KA, Bray J, Maiden MCJ, Moschioni M, Serino L, Stella M, Medini D. 2018. Potential coverage of the 4CMenB vaccine against invasive serogroup B *Neisseria meningitidis* isolated from 2009 to 2013 in the Republic of Ireland. *mSphere* 3:e00196-18. <https://doi.org/10.1128/mSphere.00196-18>.
 34. Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, De Paola R, Giuliani M, Serino L, Gray SJ, Clark SA, Findlow J, Pizza M, Ramsay ME, Ladhani SN, Borrow R. 2017. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007–08 and 2014–15: a qualitative and quantitative assessment. *Lancet Infect Dis* 17:754–762. [https://doi.org/10.1016/S1473-3099\(17\)30170-6](https://doi.org/10.1016/S1473-3099(17)30170-6).
 35. Rajam G, Stella M, Kim E, Paulos S, Boccadifuoco G, Serino L, Carlone G, Medini D. 2017. Meningococcal antigen typing system (MATS)-based *Neisseria meningitidis* serogroup B coverage prediction for the MenB-4C vaccine in the United States. *mSphere* 2:e00261-17. <https://doi.org/10.1128/mSphere.00261-17>.
 36. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R. 2013. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. *Lancet Infect Dis* 13:416–425. [https://doi.org/10.1016/S1473-3099\(13\)70006-9](https://doi.org/10.1016/S1473-3099(13)70006-9).
 37. Waško I, Hong E, De Paola R, Stella M, Moschioni M, Taha M-K, Skocznyńska A. 2016. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland. *Vaccine* 34:510–515. <https://doi.org/10.1016/j.vaccine.2015.11.070>.
 38. Abad R, Biolchi A, Moschioni M, Giuliani MM, Pizza M, Vazquez JA. 2015. A large portion of meningococcal antigen typing system-negative meningococcal strains from Spain is killed by sera from adolescents and infants immunized with 4CMenB. *Clin Vaccine Immunol* 22:357–360. <https://doi.org/10.1128/CI.00669-14>.
 39. Green LR, Lucidarme J, Dave N, Chan H, Clark S, Borrow R, Bayliss CD. 2018. Phase variation of NadA in invasive *Neisseria meningitidis* isolates

- impacts on coverage estimates for 4C-MenB, a MenB vaccine. *J Clin Microbiol* 56:e00204-18. <https://doi.org/10.1128/JCM.00204-18>.
40. Kesanopoulos K, Bratcher HB, Hong E, Xirogianni A, Papandreou A, Taha MK, Maiden MCJ, Tzanakaki G. 2018. Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: implications for 4CMenB vaccine implementation. *PLoS One* 13:e0209919. <https://doi.org/10.1371/journal.pone.0209919>.
 41. Stella M, Giuliani M, Biolchi A, Tomei S, De Paola R, Bai X, Borrow R, Lucidarme J, La Gaetana R, Toneatto D, Pizza M, Serino L, Mori E, Giuliani MM. 2020. Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269. *Hum Vaccin Immunother* 16:945-948. <https://doi.org/10.1080/21645515.2019.1688039>.
 42. Harris SL, Donald RG, Hawkins JC, Tan C, O'Neill R, McNeil LK, Perez JL, Anderson AS, Jansen KU, Jones TR. 2017. *Neisseria meningitidis* serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. *Pediatr Infect Dis J* 36:216-223. <https://doi.org/10.1097/INF.0000000000001399>.
 43. Lujan E, Partridge E, Giuntini S, Ram S, Granoff DM. 2017. Breadth and duration of meningococcal serum bactericidal activity in health care workers and microbiologists immunized with the MenB-FHbp vaccine. *Clin Vaccine Immunol* 24:e00121-17. <https://doi.org/10.1128/CVI.00121-17>.
 44. Taha M-K, Hawkins JC, Liberator P, Deghmane A-E, Andrew L, Hao L, Jones TR, McNeil LK, O'Neill RE, Perez JL, Jansen KU, Anderson AS. 2017. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. *Vaccine* 35:1530-1537. <https://doi.org/10.1016/j.vaccine.2017.01.066>.
 45. Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, Jones TR, Harris SL, O'Neill R, Radley D, Maansson R, Pregaldien JL, Ginis J, Staerke NB, Perez JL, B1971009 and B1971016 Trial Investigators. 2017. A bivalent meningococcal B vaccine in adolescents and young adults. *N Engl J Med* 377:2349-2362. <https://doi.org/10.1056/NEJMoa1614474>.
 46. Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinon-Torres F, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Lee SS, Perez JL, B1971009 and B1971016 Trial Investigators. 2017. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. *Lancet Infect Dis* 17:58-67. [https://doi.org/10.1016/S1473-3099\(16\)30314-0](https://doi.org/10.1016/S1473-3099(16)30314-0).
 47. Muse D, Christensen S, Bhuyan P, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, Perez JL. 2016. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. *Pediatr Infect Dis J* 35:673-682. <https://doi.org/10.1097/INF.0000000000001124>.
 48. Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, Ginis J, Perez JL. 2016. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. *Pediatr Infect Dis J* 35:548-554. <https://doi.org/10.1097/INF.0000000000001072>.
 49. Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Perez JL. 2016. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. *J Pediatr Infect Dis* 5:180-187. <https://doi.org/10.1093/jpids/piv064>.
 50. Reiner DM, Bhuyan P, Eiden JJ, Ginis J, Harris S, Jansen KU, Jiang Q, Jones TR, O'Neill RE, York LJ, Perez JL. 2016. Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. *Vaccine* 34:809-813. <https://doi.org/10.1016/j.vaccine.2015.12.016>.
 51. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL. 2013. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. *Vaccine* 31:1569-1575. <https://doi.org/10.1016/j.vaccine.2013.01.021>.
 52. Vesikari T, Ostergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Crowther G, Perez JL. 2016. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. *J Pediatr Infect Dis* 5:152-160. <https://doi.org/10.1093/jpids/piv039>.
 53. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL. 2013. A randomized, controlled, phase 1/2 trial of a *Neisseria meningitidis* serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. *Pediatr Infect Dis J* 32:364-371. <https://doi.org/10.1097/INF.0b013e31827b0d24>.
 54. Richmond PC, Nissen MD, Marshall HS, Lambert SB, Robertson D, Gruber WC, Jones TR, Arora A. 2012. A bivalent *Neisseria meningitidis* recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. *Vaccine* 30:6163-6174. <https://doi.org/10.1016/j.vaccine.2012.07.065>.
 55. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinon-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL. 2012. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. *Lancet Infect Dis* 12:597-607. [https://doi.org/10.1016/S1473-3099\(12\)70087-7](https://doi.org/10.1016/S1473-3099(12)70087-7).
 56. Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, Perez JL. 2012. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. *Pediatr Infect Dis J* 31:1061-1068. <https://doi.org/10.1097/INF.0b013e31826327e4>.
 57. Su EL, Snape MD. 2011. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. *Expert Rev Vaccines* 10:575-588. <https://doi.org/10.1586/erv.11.32>.
 58. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. *JAMA* 281:1520-1527. <https://doi.org/10.1001/jama.281.16.1520>.
 59. Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, Echaniz-Aviles G, Hakawi A, Kamiya H, Karachaliou A, Lucidarme J, Meiring S, Mironov K, Safadi MAP, Shao Z, Smith V, Steffen R, Stenmark B, Taha MK, Trotter C, Vazquez JA, Zhu B. 2019. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. *Expert Rev Vaccines* 18:15-30. <https://doi.org/10.1080/14760584.2019.1557520>.
 60. Sridhar S, Greenwood B, Head C, Plotkin SA, Safadi MA, Saha S, Taha MK, Tomori O, Gessner BD. 2015. Global incidence of serogroup B invasive meningococcal disease: a systematic review. *Lancet Infect Dis* 15:1334-1346. [https://doi.org/10.1016/S1473-3099\(15\)00217-0](https://doi.org/10.1016/S1473-3099(15)00217-0).
 61. Clark SA, Lucidarme J, Angel G, Lekshmi A, Morales-Aza B, Willerton L, Campbell H, Gray SJ, Ladhani SN, Wade M, Ramsay M, Yates J, Finn A, Borrow R. 2019. Outbreak strain characterisation and pharyngeal carriage detection following a protracted group B meningococcal outbreak in adolescents in South-West England. *Sci Rep* 9:9990. <https://doi.org/10.1038/s41598-019-46483-3>.
 62. Biagini M, Spinsanti M, De Angelis G, Tomei S, Ferlenghi I, Scarselli M, Rigat F, Messuti N, Biolchi A, Muzzi A, Anderloni G, Brunelli B, Cartocci E, Buricchi F, Tani C, Stella M, Moschioni M, Del Tordello E, Colaprico A, Savino S, Giuliani MM, Delany I, Pizza M, Costantino P, Norais N, Rappuoli R, Masignani V. 2016. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. *Proc Natl Acad Sci U S A* 113:2714-2719. <https://doi.org/10.1073/pnas.1521142113>.
 63. Cayour C, Akinduko AA, Mirkes EM, Lucidarme J, Clark SA, Green LR, Cooper HJ, Morrissey J, Borrow R, Bayliss CD. 2018. Clustered intergenic region sequences as predictors of factor H binding protein expression patterns and for assessing *Neisseria meningitidis* strain coverage by meningococcal vaccines. *PLoS One* 13:e0197186. <https://doi.org/10.1371/journal.pone.0197186>.
 64. Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, Borrow R, Finn A, Kahler CM, Whelan J, Vadivelu K, Richmond P. 2020. Meningococcal B

- vaccine and meningococcal carriage in adolescents in Australia. *N Engl J Med* 382:318–327. <https://doi.org/10.1056/NEJMoa1900236>.
65. Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, Bazaz R, Ganguli A, Havelock T, Neal KR, Okike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MC, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R. 2014. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. *Lancet* 384:2123–2131. [https://doi.org/10.1016/S0140-6736\(14\)60842-4](https://doi.org/10.1016/S0140-6736(14)60842-4).
66. Soeters HM, McNamara LA, Whaley M, Wang X, Alexander-Scott N, Kanadian K, Kelleher CM, MacNeil J, Martin SW, Raines N, Sears S, Vanner C, Vuong J, Bandy U, Sicard K, Patel M, Centers for Disease Control and Prevention. 2015. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. *MMWR Morb Mortal Wkly Rep* 64:606–607.